Further improvement in overall survival at 18 months to 67% for NOX-A12 combination regimen in brain cancer
TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces that another patient has reached the 18-month survival mark after start of therapy increasing overall Mehr





